BCEL vs. CANF, ALRN, TRVN, NTBL, IMNN, GTBP, GRTX, SHPH, BNTC, and EVLO
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include Can-Fite BioPharma (CANF), Aileron Therapeutics (ALRN), Trevena (TRVN), Notable Labs (NTBL), Imunon (IMNN), GT Biopharma (GTBP), Galera Therapeutics (GRTX), Shuttle Pharmaceuticals (SHPH), Benitec Biopharma (BNTC), and Evelo Biosciences (EVLO). These companies are all part of the "medical" sector.
Atreca (NASDAQ:BCEL) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Atreca has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Can-Fite BioPharma has higher revenue and earnings than Atreca. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
Atreca has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,146.62%. Can-Fite BioPharma's return on equity of -143.59% beat Atreca's return on equity.
Atreca presently has a consensus target price of $10.75, suggesting a potential upside of 4,764.25%. Can-Fite BioPharma has a consensus target price of $15.00, suggesting a potential upside of 594.44%. Given Atreca's higher probable upside, equities analysts plainly believe Atreca is more favorable than Can-Fite BioPharma.
Atreca received 94 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 4.35% of users gave Can-Fite BioPharma an outperform vote.
34.9% of Atreca shares are held by institutional investors. Comparatively, 1.5% of Can-Fite BioPharma shares are held by institutional investors. 11.3% of Atreca shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Can-Fite BioPharma had 3 more articles in the media than Atreca. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for Atreca. Can-Fite BioPharma's average media sentiment score of 0.52 beat Atreca's score of 0.45 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.
Summary
Atreca beats Can-Fite BioPharma on 9 of the 16 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools